Home > Insider Trading > Filing (0001144204-19-033657)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1512762	Coherus Biosciences Inc.	CHRS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1245624	James Healy	C/O Sofinnova Investments, Inc., 3000 Sand Hill Road, Bldg. 4, Suite 250 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Disposition	2019-06-28	200,000	$22.05	2,093,221	No	4	S	Indirect	See Footnote
Common Stock, $0.0001 Par Value	Disposition	2019-07-02	160,000	$22.61	1,933,221	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	92	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sofinnova Venture Partners VII, L.P. on August 23, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.17, inclusive. The reporting person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners VII, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners VII, L.P.